264 related articles for article (PubMed ID: 25933967)
41. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
42. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
Atkins MB; Gravis G; Drosik K; Demkow T; Tomczak P; Wong SS; Michaelson MD; Choueiri TK; Wu B; Navale L; Warner D; Ravaud A
J Clin Oncol; 2015 Oct; 33(30):3431-8. PubMed ID: 26304872
[TBL] [Abstract][Full Text] [Related]
43. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
[TBL] [Abstract][Full Text] [Related]
44. Drug interactions with sunitinib.
Bilbao-Meseguer I; Jose BS; Lopez-Gimenez LR; Gil MA; Serrano L; Castaño M; Sautua S; Basagoiti AD; Belaustegui A; Baza B; Baskaran Z; Bustinza A
J Oncol Pharm Pract; 2015 Feb; 21(1):52-66. PubMed ID: 24403097
[TBL] [Abstract][Full Text] [Related]
45. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Gallagher DJ; Al-Ahmadie H; Ostrovnaya I; Gerst SR; Regazzi A; Garcia-Grossman I; Riches J; Gounder SK; Flaherty AM; Trout A; Milowsky MI; Bajorin DF
Eur Urol; 2011 Aug; 60(2):344-9. PubMed ID: 21645967
[TBL] [Abstract][Full Text] [Related]
46. Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study.
Sousa J; Alves G; Fortuna A; Falcão A
Pharm Res; 2017 Nov; 34(11):2260-2269. PubMed ID: 28748398
[TBL] [Abstract][Full Text] [Related]
47. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
Conte JE; Golden JA; McIver M; Zurlinden E
Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
Patyna S; Haznedar J; Morris D; Freshwater K; Peng G; Sukbuntherng J; Chmielewski G; Matsumoto D
Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):204-13. PubMed ID: 19294680
[TBL] [Abstract][Full Text] [Related]
49. Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.
Bertolaso P; Gross-Goupil M; Molimard M; Cochin V; Ravaud A; Daste A
Clin Genitourin Cancer; 2017 Oct; 15(5):e885-e887. PubMed ID: 28552572
[No Abstract] [Full Text] [Related]
50. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
51. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
Kunimatsu S; Mizuno T; Fukudo M; Katsura T
Drug Metab Dispos; 2013 Aug; 41(8):1592-7. PubMed ID: 23749551
[TBL] [Abstract][Full Text] [Related]
52. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Khosravan R; Motzer RJ; Fumagalli E; Rini BI
Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
[TBL] [Abstract][Full Text] [Related]
53. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
54. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
55. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Conte JE; Golden JA; McIver M; Little E; Zurlinden E
Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
[TBL] [Abstract][Full Text] [Related]
57. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres.
Gaspar MC; Grégoire N; Sousa JJ; Pais AA; Lamarche I; Gobin P; Olivier JC; Marchand S; Couet W
Eur J Pharm Sci; 2016 Oct; 93():184-91. PubMed ID: 27531420
[TBL] [Abstract][Full Text] [Related]
58. A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy.
Nazari-Vanani R; Azarpira N; Heli H; Karimian K; Sattarahmady N
Colloids Surf B Biointerfaces; 2017 Dec; 160():65-72. PubMed ID: 28917151
[TBL] [Abstract][Full Text] [Related]
59. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract][Full Text] [Related]
60. Application of paper spray-MS in PK studies using sunitinib and benzethonium as model compounds.
Takyi-Williams J; Dong X; Gong H; Wang Y; Jian W; Liu CF; Tang K
Bioanalysis; 2015; 7(4):413-23. PubMed ID: 25747761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
